Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28420765 | 0.84 | MAPT (0.49) | CES2CES1LMNAP4HTMALDH1A1 | |
| SCHEMBL30532884 | 0.82 | LMNA (0.53) | LMNAP4HTMNAPRTL3MBTL1ALDH1A1 | |
| SCHEMBL2829058 | 0.82 | LMNA (0.53) | LMNAP4HTMNAPRTL3MBTL1ALDH1A1 | |
| SCHEMBL1690417 | 0.82 | KDM4E (0.55) | CES2CES1LMNAP4HTMNAPRT | |
| SCHEMBL7521569 | 0.82 | CES2 (0.48) | CES2CES1LMNAP4HTMNAPRT | |
| SCHEMBL11865903 | 0.81 | CES2 (0.46) | CES2CES1LMNAP4HTMNAPRT | |
| SCHEMBL450118 | 0.81 | CES2 (0.46) | CES2CES1LMNAP4HTMNAPRT | |
| Hydrochloric Acid SCHEMBL21811038 | 0.81 | LMNA (0.51) | LMNAP4HTMNAPRTL3MBTL1ALDH1A1 | |
| SCHEMBL28355505 | 0.81 | KDM4E (0.54) | CES2CES1LMNAP4HTMNAPRT | |
| SCHEMBL28438069 | 0.79 | HSD17B10 (0.56) | LMNAL3MBTL1ALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190747-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20210330671-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2021-10-28 | — | — | US | disclosed |
| US-20200383982-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2020-12-10 | — | — | US | disclosed |
| US-20190262338-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2019-08-29 | — | — | US | disclosed |
| US-20190000845-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2019-01-03 | — | — | US | disclosed |
| US-9937175-B2 | Phenyloxadiazole derivatives as PGDS inhibitors | SANOFI (FR) | 2018-04-10 | — | — | US | disclosed |
| US-20170231990-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI- AVENTIS (FR) | 2017-08-17 | — | — | US | disclosed |
| US-9469627-B2 | Phenyloxadiazole derivatives as PGDS inhibitors | SANOFI (FR) | 2016-10-18 | — | — | US | disclosed |
| EP-2486024-B1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2015-04-22 | — | — | EP | disclosed |
| EP-2486024-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI (FR) | 2012-08-15 | — | — | EP | disclosed |
| US-20120190695-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI (FR) | 2012-07-26 | — | — | US | disclosed |
| WO-2011044307-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000845-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | CES2 4827/4885CES1 3157/4885LMNA 2833/4885 |
| US-20200383982-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | CES2 4827/4885CES1 3157/4885LMNA 2833/4885 |
| US-20190262338-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | CES2 4811/4885CES1 2993/4885LMNA 2844/4885 |
| US-20120190695-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | CES2 4827/4885CES1 3157/4885LMNA 2833/4885 |
| US-20230190747-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | CES2 4827/4885CES1 3157/4885LMNA 2833/4885 |
| US-20210330671-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | CES2 4827/4885CES1 3019/4885LMNA 2952/4885 |
| US-20170231990-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | CES2 4827/4885CES1 3157/4885LMNA 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.